Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NO_LONGER_AVAILABLE

Conditions studied: COVID, Sars-CoV2, Corona Virus Infection

In brief

The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.

Key facts

Study ID

NCT04445207

Run by

Jonathan Gerber

Last updated by the study team

2023-05-25

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 12 years of age
• Covid-19 Convalescent Plasma (CCP) treatment is in line with the patient's current goals of care (i.e. recipient cannot be DNI status)
• Laboratory confirmed diagnosis of infection with SARS-CoV-2 that is severe or life threatening OR the individual is judged by the treating provider to be at a high risk of progression to severe or life-threatening disease.
• Severe COVID-19 is defined by one or more of the following:
• Dyspnea
• Respiratory frequency ≥ 30/min
• Blood oxygen saturation ≤ 93%
• Partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300
• Lung infiltrates > 50% within 24-48 hours
• Life-threatening COVID-19 is defined as one or more of the following:
• Respiratory failure
• Septic shock
• Multiple organ dysfunction or failure

You may not qualify if…

• History of prior life-threatening reactions to transfusion of blood products
• Not receiving other therapies that would preclude plasma transfusion

Where it is running

• UMass Medical School — Worcester, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.